Lupin Ltd. News and Updates

Name: Latest research reports of Lupin Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news on Lupin Ltd. from all sources in a single place.

Load latest

Lupin Ltd.

22 Sep 2020

2051.80

0.28%

Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US

Business Standard

According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

21 Sep 2020

2051.80

0.28%

Innovative diabetes drug portfolio, local partnerships help Boehringer Ingelheim take big strides in India

Moneycontrol

The German drugmaker, working on its own and through tie-ups with Lupin and Cipla, has cornered half the Sodium Glucose co-Transporter-2 market with its new class of oral anti-diabetic drugs. The rapidly growing SGLT segment currently accounts for 10 percent of the total oral anti-diabetic market, worth Rs 10,735.4 crore. Boehringer Ingelheim is also exploring partnerships to expand the market share of other drugs in its portfolio, which treat stroke, heart failure and lung cancer.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

18 Sep 2020

2051.80

0.28%

Lupin, Cipla to benefit from Perrigo's recall of asthma drug albuterol sulphate MDI in the US

Moneycontrol

Cipla has already launched the gProventil in April, while Lupin's gProAir launch is expected this month. Dublin-based Perrigo recalled the device, saying some units may fail to dispense due to clogging

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin shares hit 52-week high, Cipla shares jump 6% after Perrigo recalls albuterol sulfate

Moneycontrol | 18 Sep 2020

Lupin Ltd.

02 Sep 2020

2051.80

0.28%

Lupin launches generic rheumatoid arthritis drug 'Leflunomide' in US market

Business Standard

Drug maker Lupin on Wednesday said it has launched Leflunomide tablets, used to treat rheumatoid arthritis, in the US market. The company has launched the product in 10 mg and 20 mg strengths after receiving the approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement. The product would be manufactured at drug maker's Pithampur (Unit I) facility in Madhya Pradesh, it added. The Mumbai-based company's product is the generic equivalent of Sanofi-Aventis US LLC's Arava tablets and is indicated for the treatment of adults with active rheumatoid arthritis (RA). As per IQVIA MAT June data, Leflunomide tablets had an annual sales of around USD 42 million in the US.

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin launches generic rheumatoid arthritis drug in US market

livemint | 02 Sep 2020

Lupin Ltd.

27 Aug 2020

2051.80

0.28%

Buy Lupin; target of Rs 1130: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Lupin recommended buy rating on the stock with a target price of Rs 1130 in its research report dated August 25, 2020.

Lupin Ltd. is trading above all available SMAs

Buy Lupin; target of Rs 1085: Prabhudas Lilladher

Moneycontrol | 27 Aug 2020

Lupin Ltd.

26 Aug 2020

2051.80

0.28%

Launch of inhalation product improves Lupin's revenue visibility

Business Standard

More US launches and uptick in the Indian market are key near-term triggers

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Albuterol launch to boost Lupin US revenue, but there's little room for error

livemint | 26 Aug 2020 2 more

Lupin Ltd.

25 Aug 2020

2051.80

0.28%

Lupin gets US FDA approval for generic of blockbuster respiratory drug ProAir

livemint

The approval is timely as Albuterol MDI is a key rescue inhalation product for asthma patients who are at an increased risk of covid-related complications, the company said

Lupin Ltd. is trading above all available SMAs

Lupin share price rises 5% on US FDA approval

Moneycontrol | 25 Aug 2020

Lupin Ltd.

25 Aug 2020

2051.80

0.28%

Lupin gets USFDA nod for asthmatic symptoms prevention drug

Moneycontrol

In a regulatory filing, Lupin said it has received approval from the United States Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation.

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin gets USFDA approval for asthmatic symptoms prevention drug

Business Standard | 25 Aug 2020

Lupin Ltd.

25 Aug 2020

2051.80

0.28%

Event Update - US FDA approval of gProAir HFA to lift earnings - BUY

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

LPC received approval for gProAir HFA (Albuterol Sulfate) that offers a revenue opportunity of US$140-155m over next 8 quarters beginning from 2QFY21E. The total market size of Albuterol Sulfate Inhalation Aerosol is US$2.9bn of which 44% market share is held by ProAir. While there are 9 companies in Albuterol (including 3 AG, 6 generics), LPC and Perrigo are the only generics in gProAir and plans to launch their generics in Aug CY20. We expect LPC can potentially have 5% Rx share of the Albuterol Sulfate...

Lupin Ltd. is trading above all available SMAs

Is Lupin Ltd. worth buying?

923 Votes:

Buy 72.81%

Sell 17.44%

Hold 9.75%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf